Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.1
5.6
Journals
IJMS
Special Issues
Mucosal Delivery of Vaccines
ijms-logo
Submit to IJMS Review for IJMS Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Mucosal Delivery of Vaccines

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Immunology".

Deadline for manuscript submissions: closed (30 December 2023) | Viewed by 5382

Special Issue Editor

Dr. Claire Monge

E-Mail Website
Guest Editor
Tissue Biology and Therapeutic Engineering Laboratory, Institute of Biology and Chemistry of Proteins, UMR 5305, CNRS/University Claude Bernard Lyon 1, 7 Passage du Vercors, CEDEX 07, 69367 Lyon, France
Interests: seaweed; sulfated polysaccharide; respiratory virus; approved antivirals; antiviral activity; vaccine; vaccine adjuvant; sublingual
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

I am pleased to invite you to contribute to this Special Issue of the International Journal of Molecular Sciences (IJMS) entitled “Mucosal Delivery of Vaccines”. This Special Issue will cover a selection of recent research topics and current review articles reporting the latest updates on the development of vaccines delivered through the mucosa.

Mucosal delivery of vaccines offers the opportunity to directly target the mucosal immune system for an improved mucosal response. Many mucosal sites have been explored during the last decades. Nonetheless, there are still few mucosal vaccines available on the market due to the challenging nature of their development.

This Special Issue aims at gathering publications concerning the biological and/or technological challenges of mucosal vaccines:

  • Design/production of vectors with mucoadhesive or mucopenetrating properties;
  • Development or study of mucosal adjuvants;
  • Advances in in vitro mucosal models to avoid animal experiments;
  • Induced immune responses after mucosal administration;
  • Vaccination protocols including a mucosal administration (homologous or heterologous).

Studies from any type of mucosal administration will be in the scope of this Special Issue, as well as any type of vaccine (viral and non-viral vectors, attenuated/inactivated, subunit, mRNA vaccines, etc.).

Dr. Claire Monge
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • mucosal administration
  • vaccine
  • mucosal immunity
  • mucosal adjuvants
  • mucoadhesive polymers
  • polysaccharides

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

17 pages, 3807 KiB  
Article
IgGκ Signal Peptide Enhances the Efficacy of an Influenza Vector Vaccine against Respiratory Syncytial Virus Infection in Mice
by Anastasia Pulkina, Kirill Vasilyev, Arman Muzhikyan, Mariia Sergeeva, Ekaterina Romanovskaya-Romanko, Anna-Polina Shurygina, Marina Shuklina, Andrey Vasin, Marina Stukova and Andrej Egorov
Int. J. Mol. Sci. 2023, 24(14), 11445; https://doi.org/10.3390/ijms241411445 - 14 Jul 2023
Cited by 5 | Viewed by 1454
Abstract
Intranasal vaccination using influenza vectors is a promising approach to developing vaccines against respiratory pathogens due to the activation of the mucosa-associated immune response. However, there is no clear evidence of a vector design that could be considered preferable. To find the optimal [...] Read more.
Intranasal vaccination using influenza vectors is a promising approach to developing vaccines against respiratory pathogens due to the activation of the mucosa-associated immune response. However, there is no clear evidence of a vector design that could be considered preferable. To find the optimal structure of an influenza vector with a modified NS genomic segment, we constructed four vector expressing identical transgene sequences inherited from the F protein of the respiratory syncytial virus (RSV). Two vectors were designed aiming at transgene accumulation in the cytosol. Another two were supplemented with an IgGκ signal peptide prior to the transgene for its extracellular delivery. Surprisingly, adding the IgGκ substantially enhanced the T-cell immune response to the CD8 epitope of the transgene. Moreover, this strategy allowed us to obtain a better protection of mice from the RSV challenge after a single intranasal immunization. Protection was achieved without antibodies, mediated by a balanced T-cell immune response including the formation of the RSV specific effector CD8+ IFNγ+/IL10+-producing cells and the accumulation of Treg cells preventing immunopathology in the lungs of infected mice. In addition to the presented method for optimizing the influenza vector, our results highlight the possibility of achieving protection against RSV through a respiratory-associated T-cell immune response alone. Full article
(This article belongs to the Special Issue Mucosal Delivery of Vaccines)
►▼ Show Figures

Figure 1

22 pages, 3668 KiB  
Article
Preclinical Evaluation of TB/FLU-04L—An Intranasal Influenza Vector-Based Boost Vaccine against Tuberculosis
by Anna-Polina Shurygina, Natalia Zabolotnykh, Tatiana Vinogradova, Berik Khairullin, Markhabat Kassenov, Ainur Nurpeisova, Gulbanu Sarsenbayeva, Abylai Sansyzbay, Kirill Vasilyev, Janna Buzitskaya, Andrey Egorov and Marina Stukova
Int. J. Mol. Sci. 2023, 24(8), 7439; https://doi.org/10.3390/ijms24087439 - 18 Apr 2023
Cited by 5 | Viewed by 1556
Abstract
Tuberculosis is a major global threat to human health. Since the widely used BCG vaccine is poorly effective in adults, there is a demand for the development of a new type of boost tuberculosis vaccine. We designed a novel intranasal tuberculosis vaccine candidate, [...] Read more.
Tuberculosis is a major global threat to human health. Since the widely used BCG vaccine is poorly effective in adults, there is a demand for the development of a new type of boost tuberculosis vaccine. We designed a novel intranasal tuberculosis vaccine candidate, TB/FLU-04L, which is based on an attenuated influenza A virus vector encoding two mycobacterium antigens, Ag85A and ESAT-6. As tuberculosis is an airborne disease, the ability to induce mucosal immunity is one of the potential advantages of influenza vectors. Sequences of ESAT-6 and Ag85A antigens were inserted into the NS1 open reading frame of the influenza A virus to replace the deleted carboxyl part of the NS1 protein. The vector expressing chimeric NS1 protein appeared to be genetically stable and replication-deficient in mice and non-human primates. Intranasal immunization of C57BL/6 mice or cynomolgus macaques with the TB/FLU-04L vaccine candidate induced Mtb-specific Th1 immune response. Single TB/FLU-04L immunization in mice showed commensurate levels of protection in comparison to BCG and significantly increased the protective effect of BCG when applied in a “prime-boost” scheme. Our findings show that intranasal immunization with the TB/FLU-04L vaccine, which carries two mycobacterium antigens, is safe, and induces a protective immune response against virulent M. tuberculosis. Full article
(This article belongs to the Special Issue Mucosal Delivery of Vaccines)
►▼ Show Figures

Figure 1

Review

Jump to: Research

19 pages, 1913 KiB  
Review
The Bacterial Spore as a Mucosal Vaccine Delivery System
by Anella Saggese, Loredana Baccigalupi, Giuliana Donadio, Ezio Ricca and Rachele Isticato
Int. J. Mol. Sci. 2023, 24(13), 10880; https://doi.org/10.3390/ijms241310880 - 29 Jun 2023
Cited by 6 | Viewed by 1788
Abstract
The development of efficient mucosal vaccines is strongly dependent on the use of appropriate vectors. Various biological systems or synthetic nanoparticles have been proposed to display and deliver antigens to mucosal surfaces. The Bacillus spore, a metabolically quiescent and extremely resistant cell, has [...] Read more.
The development of efficient mucosal vaccines is strongly dependent on the use of appropriate vectors. Various biological systems or synthetic nanoparticles have been proposed to display and deliver antigens to mucosal surfaces. The Bacillus spore, a metabolically quiescent and extremely resistant cell, has also been proposed as a mucosal vaccine delivery system and shown able to conjugate the advantages of live and synthetic systems. Several antigens have been displayed on the spore by either recombinant or non-recombinant approaches, and antigen-specific immune responses have been observed in animals immunized by the oral or nasal route. Here we review the use of the bacterial spore as a mucosal vaccine vehicle focusing on the advantages and drawbacks of using the spore and of the recombinant vs. non-recombinant approach to display antigens on the spore surface. An overview of the immune responses induced by antigen-displaying spores so far tested in animals is presented and discussed. Full article
(This article belongs to the Special Issue Mucosal Delivery of Vaccines)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop